Now Scorpius Holdings: SCPX [ previously NightHawk Biosciences :NHWK & Heat Biologics, Inc.: HTBX), a biopharmaceutical company, focuses on developing immunotherapies to activate patient's immune system against cancer through T-cell activation and expansion. The company's T-cell activation platform, includes two variations for intradermal administration, such as immune pan-antigen cytotoxic therapy, an allogenic cell-based, T-cell-stimulating platform that functions as an immune activator to stimulate and expand T-cells; and combination pan-antigen cytotoxic therapy, a dual-acting immunotherapy, which delivers antigen driven T-cell activation and specific co-stimulation in a single product.